189 filings
Page 3 of 10
8-K
zruq45yv2j
16 Feb 22
Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion
4:32pm
8-K
ist22qpl328szlx
20 Jan 22
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer
12:00am
8-K
fx2yv pvevy737
9 Dec 21
Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors
8:01am
8-K
owoh m36rljnr7n
15 Nov 21
Departure of Directors or Certain Officers
7:01am
8-K
pjaikl14e d5ib
10 Nov 21
Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results
4:29pm
8-K
u8fxspvtol y3
19 Aug 21
Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas
4:12pm
8-K
l49qc35c3q0u872
10 Aug 21
Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results
4:08pm
8-K
zjmkekeiomb2yv961l2
28 Jul 21
Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility
4:36pm
8-K
8e298hrm2itn22
6 Jul 21
Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML
7:23am
8-K
rlri4j jksfuww
11 Jun 21
Submission of Matters to a Vote of Security Holders
8:00am
8-K
8woq5
12 May 21
Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results
4:17pm
8-K
bogqr2gxymtc
16 Mar 21
CORPORATE PRESENTATION March 2021
5:16pm
8-K
5ug23a28
9 Mar 21
Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results
4:36pm
8-K
13sud a4rx
3 Mar 21
Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant
7:41am
8-K
aqnik0z7
13 Jan 21
Regulation FD Disclosure
7:43am
8-K
1b7v4vi
5 Jan 21
Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial
4:01pm
8-K
4o8xzln0aq1y65q
9 Nov 20
Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results
4:18pm
8-K
nqb 618ghkyq4dmm
10 Aug 20
Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results
4:29pm
8-K
eiqrul 9bw8yz7bf
30 Jun 20
Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates
9:13am
8-K
f6enyo1itpkq
23 Jun 20
Regulation FD Disclosure
8:51am